Loading...

Microba Life Sciences Limited

MAP.AX•ASX
HealthcareMedical - Diagnostics & Research
$0.17
$0.005(3.03%)

Microba Life Sciences Limited (MAP.AX) Stock Overview

Explore Microba Life Sciences Limited’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
123.06%
↑ 123.06%
Profit Growth
$-0.04
↓ 57.24%
EPS Growth
$-0.04
↓ 27.56%
Operating Margin
-112.15%
↓ 32.71%
ROE
-47.90%
↓ 57.24%
Dividend Yield
0.00%
Analyst Recommendations data is not available for MAP.AXAnalyst Recommendations details for MAP.AX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; Databank, for discovery of therapeutic leads, consumer health innovations, and diagnostic biomarkers; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases. The company was incorporated in 2017 and is based in Brisbane, Australia.

CEO

Dr. Luke Reid

Headquarters

324 Queen Street, Brisbane, QLD

Founded

2022

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.